Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer.

@article{Heinemann2000GemcitabineAC,
  title={Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer.},
  author={Volker Heinemann and H. Wilke and H G Mergenthaler and Michael Clemens and H A Koenig and Hans Jochen Illiger and Michael B Arning and Andreas Schalhorn and Kurt Possinger and Ulrich Fink},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2000},
  volume={11 11},
  pages={1399-403}
}
BACKGROUND This phase II study was initiated to determine the efficacy and safety of gemcitabine plus cisplatin in patients with pancreatic cancer. PATIENTS AND METHODS Gemcitabine 1000 mg/m2 was given on days 1, 8, and 15 of a 28-day schedule, and cisplatin 50 mg/m2 on days 1 and 15 to chemonaive patients with locally advanced or metastatic pancreatic cancer. RESULTS Of the 41 patients enrolled (median age 57, and 61% male), median Karnofsky performance status was 80%. Patients received a… CONTINUE READING